China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
PARIS and CAMBRIDGE, Mass., Oct. 04, 2017 -- Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks:
| October | |||
| |||
| Date: | Wednesday, October 11 | ||
| Time | 3:45pm Eastern Time | ||
| Location: | Westin New York Grand Central, Assembly Room | ||
| |||
| Date: | Thursday, October 12 | ||
| Time: | 2:30pm Eastern Time | ||
| Location: | Westin New York Grand Central | ||
| |||
| Date: | Friday, October 13 | ||
| Time: | 12:00pm – 1:30pm Eastern Time | ||
| Location | Lotte New York Palace Hotel | ||
| Webcast: http://lifesci.rampard.com/20171013/reg.jsp | |||
| November | |||
| |||
| Date: | Tuesday, November 14 & Wednesday, November 15 | ||
| Time: | TBD | ||
| Location | Waldorf Hilton | ||
About Lysogene
Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.
Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475).
For more information: www.lysogene.com.
Contacts
| Media: | Investors: | |
| Europe | ||
| Annie-Florence Loyer | Chris Maggos | |
| NewCap | LifeSci Advisors | |
| [email protected] | [email protected] | |
| + 33 6 88 20 35 59 | +41 79 367 6254 | |
| + 33 1 44 71 00 12 | ||
| North America | ||
| Marion Janic | ||
| RooneyPartners | ||
| [email protected] | ||
| + 1 (212) 223-4017 |
